The observed decrease in Myl2 and Actc1 transcript levels suggests that these treatments may contribute to cellular dysfunctions typically associated with idiopathic dilated cardiomyopathy (IDC). The gene discussed is MYL2; the disease is idiopathic dilated cardiomyopathy.